Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[123I]MNI-390
- Development stage
- Phase 1
- Lead developer
- Institute for Neurodegenerative Disorders
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[123I]MNI-390 is an investigational radiopharmaceutical developed by the Institute for Neurodegenerative Disorders for use as a Single Photon Emission Computed Tomography (SPECT) imaging biomarker. It is a small molecule ligand labeled with the radioisotope Iodine-123, designed to cross the blood-brain barrier and bind with high affinity to beta-amyloid protein plaques, which are characteristic pathological features of Alzheimer's disease. The agent is intended to facilitate the in vivo visualization and quantification of amyloid burden, potentially serving as a diagnostic tool or a marker for monitoring disease progression and therapeutic efficacy in clinical trials. In clinical evaluation, [123I]MNI-390 has been studied in Phase 1 trials to characterize its brain uptake, washout kinetics, and metabolic profile in both Alzheimer's patients and healthy elderly controls.
- Other names
- [123I]MNI390
02
Targets
Amyloid-beta aggregate (N-terminal epitope)
Beyond the preview
Go deeper on [123I]MNI-390.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [123I]MNI-390.